ARS Pharma appoints Donn Casale as President effective June 1, 2026

ARS Pharmaceuticals, Inc.

• Donn Casale, 53, most recently Chief Commercial Officer at Dynavax (acquired by Sanofi), joins as President.
• Casale will receive an annual base salary of $575,000 and target annual discretionary bonus of 45% of base.
• Stock option grant valued at ~$6M under 2020 Equity Incentive Plan; exercise price = grant date closing price.
• Option vests 25% after one year, then monthly over 36 months; subject to continued employment.
• He replaces Richard Lowenthal as President; Lowenthal remains CEO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.